Centro Alfa-1 Granada

Research on Genetic Diseases Today, November 10, 2020, we celebrate Science Day. We want to make special mention of the evolution in genetic treatments. Evolution in science Genetic therapy uses genetic material to treat diseases of this group, which, as we already know, Alpha 1 Antitrypsin Deficiency is part of it. This therapy tries to

The human trial begins, of the treatment that acts on the liver, due to the protein Alpha-1 Antitrypsin. Almost all cases of AATD are caused by a single mutation in the A1AT gene, known as the ‘Z mutation’. Z Factor, the Cambridge-based drug development company, has administered the first human volunteer ZF874, their novel treatment

Takeda and Arrowhead collaborate to develop and commercialize ARO-AAT Takeda and Arrowhead Team Up to Unveil Active Liver, Targeted to the Alpha-1 Community. “This agreement also supports the strategy of selectively partnering to continue investing in the targeted RNAi molecule (TRiMTM) platform”. They also come together to manage the growing portfolio of RNAi therapeutics targeting

The second phase of treatment is already underway Arrowhead ARO-AAT Phase 2 interim results in patients with alpha-1 liver disease demonstrate improvements in key parameters after six months of treatment. PASADENA, California Arrowhead Pharmaceuticals Inc. announced this September 2020 interim positive 24-week liver biopsy results in four subjects from AROAAT2002. An open-label phase 2 clinical

Recommendations to all health workers The Spanish Society of Preventive Medicine, Public Health and Hygiene makes 5 fundamental recommendations to prevent the transmission of the virus in the social and work environment. The role of health center staff is very important. Preventing the transmission of SARS-CoV-2 is essential. 1. Maximize distances Always keep a safe

Nazli Khodayari, PhD receives the 2020 John W. Walsh Translational Research Award for the research grant entitled “Novel Biomarkers for Alpha-1-Antitrypsin Mediated Liver Disease in Circulating Exosomes”. In serch of the cure This honorable award was created in October 2016 and is named after John W. Walsh, co-founder of the Alpha-1 Foundation., a visionary man

Many Alphas live a healthy and fulfilling life with proper treatment and lifestyle changes. With planning, education, support and most importantly, patience, it is possible to continue to work, travel and exercise and do the many things that you enjoy doing. ¿What now? When you or your child is diagnosed with Alpha-1, there are some

Published in “Gastroenterology” The Alpha1-Liver Team from Aachen, Germany, which coordinates the European study group for alpha1-antitrypsin deficiency-related liver disease, has published the latest results on liver involvement in mild alpha1-antitrypsin deficiency in the renowned journal Gastroenterology. This work appears a year after the contribution that focused on the liver phenotype in severe alpha1-antitrypsin deficiency